Flexibility

Uniquely Velphoro: Flexible administration options add to patient convenience and control1

  (1:15 minutes)

See how flexible administration can help adherence1

  • Patients can choose the way they take Velphoro:
    break, crush, or chew
  • Taken just before, during, or just after a meal or snack
  • Can be taken without water, for all-day convenience

Uniquely Velphoro: Data show giving patients choices improved acceptance†3

 

When given a choice to chew Velphoro or break and swallow†3:

 

Nearly 

8 out of 10

 patients accepted Velphoro

89%

of patients chose
to break and swallow

Velphoro dosing is simple for patients, easy for healthcare providers1

Recommended

starting dose

1 tablet per meal
=
3 tablets per day1

Titrate by 1 tablet per day,

as required 

Increase by 1 tablet per day
(not per meal) 
until serum phosphorus 
levels are under control, 
as often as weekly1

Maintain 

phosphorus control

Most patients required
3-4 tablets per day,
HALF the pills
vs some other binders1,4

 

High adherence demonstrated in clinical and real-world settings4,5

 

 

Adherence in the largest registrational phosphate binder clinical study (N=1,054)‡4

 

Medication possession ratio (MPR) in a 6-month,

real-world analysis of pharmacy service data (n=30)§5

In the real-world analysis§5:

  • Adherence was measured by the MPR, which was calculated as the number of days for which there was active binder supply5
  • Analysis of MPR in a subset of patients (those not enrolled in the automated refill service) suggests that improvement in MPR may be the result of better adherence to therapy (MPR improvement from 0.68 to 0.80)5

MPR >80% is generally defined as having good medication adherence6

*Presenter is a paid speaker and has been compensated for their time.

†Prospective analysis of 105 patients on hemodialysis to assess acceptance and strategies that support compliance in clinical practice. All patients were on a phosphate binder: at baseline, 57 were switched to Velphoro and 48 maintained their baseline treatment. Patients were informed about various modes of administration and were permitted to adapt administration based on preference.3

‡A 52-week, open-label, active-controlled, phase 3 study evaluated the safety and efficacy of Velphoro in lowering serum phosphorus levels in patients (N=1,054) with chronic kidney disease on hemodialysis or peritoneal dialysis. In the titration phase (first 24 weeks), patients were randomized to receive either Velphoro or sevelamer carbonate to establish the noninferiority of Velphoro to sevelamer carbonate in lowering serum phosphorus at 12 weeks (secondary endpoint). The following withdrawal phase (weeks 24 to 27, n=93) established the superiority of Velphoro with an effective maintenance dose over a placebo-like low dose (primary endpoint). During a final long-term maintenance phase (weeks 28 to 52, n=658), patients continued phosphate binder treatment according to their original randomization for the assessment of long-term efficacy, safety, and tolerability.1

§A retrospective analysis of deidentified pharmacy data from adult hemodialysis patients (n=490) who were enrolled with the DaVita pharmacy service for at least 6 months. Subjects were patients who converted to Velphoro monotherapy from another phosphate binder during routine care between April 2014 and September 2016. The decision to switch phosphate binders (PBs) was made on a clinical basis and the reasons underlying this change were not available. Primary outcomes were total daily PB pill burden, total PB medication possession ratio, serum phosphorus, and percentage of patients with serum phosphorus ≤5.5 mg/dL.5

References: 1. Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America: 2024. 2. Lanz M, Baldischweiler J, Kriwet B, Schill J, Stafford J, Imanidis G. Chewability testing in the development of a chewable tablet for hyperphosphatemia. Drug Dev Ind Pharm. 2014;40(12):1623-1631. 3. Arenas Jiménez MD, Navarro González JF. How to improve adherence the captors of phosphorus on hemodialysis: experience in real life with sucroferric oxyhydroxide. Nefrologia (Engl Ed). 2020;40(6):640-646. 4. Floege J, Covic AC, Ketteler M, et al; on behalf of the Sucroferric Oxyhydroxide Study Group. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015;30(6):1037-1046. 5. Gray K, Ficociello LH, Hunt AE, Mullon C, Brunelli SM. Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide. Int J Nephrol Renovasc Dis. 2019;12:1-8. 6. Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019;92(2):117-122.

INDICATION

Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in adult and pediatric patients 9 years of age and older with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

  • Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed. Do not swallow whole.
  • Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
  • In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
  • Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

Velphoro is available by prescription only. For additional Safety Information, please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care Customer Service at 1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is intended for use by US healthcare professionals only.

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451

Fresenius Medical Care Renal Pharmaceuticals

© 2021, 2025 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care and the triangle logo are trademarks for which Fresenius Medical Care AG holds rights. Velphoro is a trademark of Vifor Fresenius Medical Care Renal Pharma Ltd. All other trademarks are the property of their respective owners.